Skip to content

Study · Measured the body's own peptide · 2023

3 results

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.

Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, Sailer CO, Eckert A, Heinrichs M, Liechti ME, Christ-Crain M

The lancet. Diabetes & endocrinology13 May 2023Cited by 56 (Europe PMC)

PMID37192642 (opens in a new tab)DOI10.1016/s2213-8587(23)00120-1 (opens in a new tab)PepBankPUB-37192642
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In patients with arginine vasopressin deficiency, the MDMA-induced plasma oxytocin AUC was lower than in healthy controls.

    In plain wordsIn patients with arginine vasopressin deficiency, the body's own oxytocin response to MDMA was much smaller than in healthy adults.

    Peptide
    Oxytocin
    Outcome
    DecreaseOxytocin AUC after MDMA, patients versus healthy controls
    Study

    n = 30

    Comparator
    Healthy controls
    Analysis
    Primary
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    oxytocin AUC difference, controls higher
    82%
    healthy controls vs patients

    Source sentences

    Summary
    The effect of MDMA on oxytocin was significantly different between groups: the AUC for oxytocin was 82% (95% CI 70-186) higher in healthy controls than in patients (difference 85 678 pg/mL [95% CI 63 356-108 000], p<0·0001).
    3 context sentences
    Summary · context
    The primary outcome was the area under the plasma oxytocin concentration curve (AUC) after drug intake.
    Summary · context
    This single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial included patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls (matched 1:1 by age, sex, and BMI) and was conducted at the University Hospital Ba…
    Summary · context
    Between Feb 1, 2021, and May 1, 2022, we recruited 15 patients with arginine vasopressin deficiency (central diabetes insipidus) and 15 healthy controls.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelRandomized controlled trialOther

    In healthy controls, plasma oxytocin concentration rose strongly in response to a single 100 mg oral MDMA dose.

    In plain wordsIn healthy adults, the body's own oxytocin rose strongly in blood after MDMA.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin response to MDMA in healthy controls
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    baseline plasma oxytocin
    77 pg/mL
    healthy controls
    plasma oxytocin increase
    659 pg/mL
    healthy controls after MDMA

    Source sentences

    Summary
    In healthy controls, median plasma oxytocin concentration was 77 pg/mL (IQR 59-94) at baseline and increased by 659 pg/mL (355-914) in response to MDMA, resulting in an AUC of 102 095 pg/mL (41 782-129 565)
    2 context sentences
    Summary · context
    This single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial included patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls (matched 1:1 by age, sex, and BMI) and was conducted at the University Hospital Ba…
    Summary · context
    Between Feb 1, 2021, and May 1, 2022, we recruited 15 patients with arginine vasopressin deficiency (central diabetes insipidus) and 15 healthy controls.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelRandomized controlled trialOther

    In patients with arginine vasopressin deficiency, plasma oxytocin concentration increased only slightly in response to a single 100 mg oral MDMA dose.

    In plain wordsIn patients with arginine vasopressin deficiency, the body's own oxytocin rose only slightly in blood after MDMA.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin response to MDMA in patients with arginine vasopressin deficiency
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    baseline plasma oxytocin
    60 pg/mL
    patients
    plasma oxytocin increase
    66 pg/mL
    patients after MDMA

    Source sentences

    Summary
    in patients, baseline oxytocin concentration was 60 pg/mL (51-74) and only slightly increased by 66 pg/mL (16-94) in response to MDMA, resulting in an AUC of 6446 pg/mL (1291-11 577).
    2 context sentences
    Summary · context
    This single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial included patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls (matched 1:1 by age, sex, and BMI) and was conducted at the University Hospital Ba…
    Summary · context
    Between Feb 1, 2021, and May 1, 2022, we recruited 15 patients with arginine vasopressin deficiency (central diabetes insipidus) and 15 healthy controls.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT04648137

Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls

University Hospital, Basel, Switzerlandn = 305 Feb 2021 to 11 Apr 2022

Diabetes Insipidus

Trial pageClinicalTrials.govUpdated 13 Apr 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.